Industry progress report on neuro-oncology: Biotech update 2013.
For the second time, The Brain Tumor Center of the Weill Cornell Brain and Spine Center, in collaboration with Voices Against Brain Cancer, hosted The Brain Tumor Biotech Summit in New York City in June 2013. After a very successful first summit in 2012, this innovative event has established a platform for intensive networking between neuro-oncologists, neurosurgeons, neuroscientists, members of the biotechnology and pharmaceutical communities, members of the financial community and leaders of non-profit organizations. This year's summit highlighted dendritic cell vaccines, novel antibody, heat shock protein and targeted therapies as well as exosome technologies, MRI-guided therapies and other novel drug delivery tools. This report presents a short overview of the current progress in brain tumor research and therapy as presented at the 2013 Brain Tumor Biotech Summit.
Department of Neurological Surgery, Weill Cornell Medical College, New York, NY, USA, MalteOttenhausen@web.de.
Malte
M
Ottenhausen
Imithri
I
Bodhinayake
Matei
M
Banu
Kartik
K
Kesavabhotla
Ashley
A
Ray
John A
JA
Boockvar
D001709:Biotechnology / Q000639:trends*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D004345:Drug Industry; D006801:Humans; D058990:Molecular Targeted Therapy; D004364:Pharmaceutical Preparations; D058028:Research Report
D019496:Cancer Vaccines; D004364:Pharmaceutical Preparations